The main goal of this study is to assess 64Cu-DOTHA2-PSMA’s therapeutic potential by determining its influence on survival and tumor size, as well as its general toxicity profile on organs of interest for PSMA radioligand therapy in comparison to control and to clinically used 177Lu-PSMA-617. The gene discussed is FOLH1; the disease is neoplasm.